Drug Profile
PF 4995274
Alternative Names: PF-04995274; PF-4995274Latest Information Update: 14 Nov 2022
Price :
$50
*
At a glance
- Originator Pfizer
- Developer Pfizer; University of Oxford
- Class Antidementias
- Mechanism of Action Serotonin 4 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease; Depressive disorders
Most Recent Events
- 14 Nov 2022 Discontinued - Phase-I for Depressive disorders in United Kingdom (PO)
- 29 Jul 2022 Pfizer completes the RESTAND phase I trial for Depression in United Kingdom (NCT03516604)
- 28 Jun 2021 No recent reports of development identified for phase-I development in Depressive disorders in United Kingdom (PO, Tablet)